Actinium Pharmaceuticals (NYSE: ATNM) Jumps Over 30% on Massive Volumes

Actinium Pharmaceuticals Inc. – NYSE: ATNM

Actinium Pharmaceuticals gained over 30% in today’s trading on exceptionally heavy volumes. ATNM, traded on the NYSE, has an average daily volume of 275k, but today over 5.5 million shares traded hands.

New York, NY-based Actinium Pharmaceuticals is a biotech company that develops innovative targeted payload immunotherapies for the treatment of advanced cancers. The Company’s radioimmunotherapy product candidates are based on the combination of the cancer targeting precision of monoclonal antibodies (mAb) that seek out specific types of cells combined with the cytotoxic killing power of radioisotopes that unleash their energy once they have reached their target.

Actinium’s lead product is Iomab-B and is in its crucial Phase 3 clinical trial. Iomab-B is a myeloablative therapy, designed to destroy a patient’s bone marrow so that a patient can receive bone marrow from a donor via a transplant. Also in Actiniumn’s pipeline is its Alpha Particle Immunotherapy (APIT) platform. Being 100 times more powerful than beta particles, alpha therapy is effective in cancers that are not sensitive to beta irradiation such as victims of Acute Myeloid Leukemia (AML). AML treatment utilizing APIT has demonstrated extremely high cancer cell kill levels.

On January 27 – 28, 2017, in Dallas, TX, Chief Medical Officer, Dr. Mark Berger will present at the 3rd Annual Think Tank on Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms. Dava Oncology is sponsoring the event as part of their Oncology Meeting Innovations program. Dr. Berger’s talk will focus on Actinium’s Iomab-B.

ATNM shares took a 20% dive in September when the company announced a public offering of an additional 8 million shares at $1.25 a piece plus offering the underwriters a 30-day option on an additional 15% of the sold stock. The price gapped down to below $1.40 and broke the $1 barrier in late October. Shares rebounded slightly and traded around the $1 handle until today when the stock took off and closed at $1.36 – just two cents short of the daily high.

Actinium Pharmaceuticals has yet to post any sales but institutions own over 10% of its shares – a fact which comforts some investors. ATNM had its largest earnings loss in 2012 when the company announced a loss of $7.58 per share. Earnings have never been positive; the last three years have seen per share losses under $1 with 2015 posting a loss of $0.55. Two firms follow Actinium Pharmaceuticals and both rate ATNM shares as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/3/2017
Ticker Symbol ATNM
Last Price a/o 3:59 PM EST  $                      1.36
Average Volume                    274,270
Market Cap (mlns)  $                    57.42
Sales (mlns)
Shares Outstanding (mlns) 55.75
Share Float (mlns) 51.06
Shortable Yes
Optionable Yes
Inside Ownership 8.50%
Short Float 2.31%
Short Interest Ratio 4.3
Quarterly Return 4.99%
YTD Return 17.17%
Year Return -50.00%

Pulmatrix, Inc. (Nasdaq: PULM) Resting After Massive Gains

Pulmatrix, Inc. – Nasdaq: PULM

Pulmatrix shares have had quite a ride recently. In mid-January PULM, traded on the Nasdaq, were traing below $1. Yesterday they traded over $6 and are now down to $4.87 in early trading on volumes near 10 million – average daily volume is just under three million.

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases. Three days ago the company announced that it has entered into a definitive agreement with institutional investors to purchase approximately $5.0 million of shares of common stock in a registered direct offering. That temporarily halted the stock’s rapid rise on dilution worries.

Pulmatrix first reported sales in 2015 and posted a figure of $1.2 million. Since 2011 PULM shares have experienced negative EPS. In 2014 PULM lost $3.47 per share, and in 2015 the company posted an EPS loss of $3.24. No firms or analysts follow shares of PULM.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/3/2017
Ticker Symbol PULM
Last Price a/o 11:12 AM EST  $                    13.26
Average Volume                2,940,000
Market Cap (mlns)  $                    74.92
Sales (mlns) $1.00
Shares Outstanding (mlns) 14.69
Share Float (mlns) 13.19
Shortable No
Optionable No
Inside Ownership 26.44%
Short Float 0.15%
Short Interest Ratio 0.01
Quarterly Return 325.00%
YTD Return 764.41%
Year Return 82.14%

Cerulean Pharma (Nasdaq: CERU) Shares Rise on Sale Speculation

Cerulean Pharma, Inc. – Nasdaq: CERU

An announcement by the Board of Cerulean Pharma to explore strategic alternatives has sent shares higher on speculation that a sale may be in the works. CERU, traded on the Nasdaq under ticker CERU, ended trading Thursday at $0.93 and have reached a high of $1.49 in early trading on heavy volumes. The announcement was likely due to a Phase 2 clinical trial failure, in August, which led to Cerulean cutting half its workforce.

Waltham, MA-based Cerulean Pharma develops products to improve treatment options for cancer victims. The company developed the Dynamic Tumor Targeting™ Platform designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Cerulean’s lead platform-generated NDC clinical candidate, CRLX101, is in multiple clinical trials. Our lead indication is ovarian cancer. Our second platform-generated NDC clinical candidate, CRLX301, is in Phase 2a clinical development for the treatment of advanced solid tumors.

Cerulean sales peaked in 2012 when the company posted a figure of $600k. No sales were reported for 2015. CERU shares have never experienced positive EPS – losing more than $1.20 EPS in each of the past five years. CERU lost $1.56 EPS in 2015. Three firms rate CEU shares. One rates them as a “Strong Buy”, and the other rates CERU as a “Hold”. Their consensus price target is $1.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/3/2017
Ticker Symbol CERU
Last Price a/o 9:23 AM EST  $                      1.34
Average Volume                    328,570
Market Cap (mlns)  $                    25.49
Sales (mlns)
Shares Outstanding (mlns) 27.38
Share Float (mlns) 24.66
Shortable Yes
Optionable Yes
Inside Ownership 1.30%
Short Float 2.68%
Short Interest Ratio 2.01
Quarterly Return 24.82%
YTD Return 31.46%
Year Return -58.99%

Keryx Therapeutics (Nasdaq: KERX) Up over 15% on Heavy Volume

Keryx Biopharmaceuticals Inc. – Nasdaq: KERX

Boston, MA-based Keryx Pharmaceuticals are up over 15% on heavy volume and have gained almost 40% in the last year. KERX, traded on the Nasdaq, has an average daily volume of 1.58 million but have already traded over 2.5 million at the time of this writing.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide treatments to people with renal disease. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine, Auryxia tablets.

On January 12th, the company announced the publication of results from its pivotal Phase 3 study evaluating ferric citrate for iron deficiency anemia in non-dialysis-dependent chronic kidney disease in the online issue of the Journal of the American Society of Nephrology.

“The results shown in this pivotal study demonstrated that ferric citrate, if approved for this indication, could provide an important new treatment option for people living with chronic kidney disease and iron deficiency anemia who are not on dialysis,” said Steven Fishbane, M.D., chief of nephrology for North Shore University Hospital and Long Island Jewish Medical Center.

Keryx Biopharmaceuticals sales have increased each year since 2013 and posted a figure of $13.7 million in 2015. KERX shareholders have not experienced the same increase in their EPS. KERX EPS has been negative for the past five years and in 2015 KERX had an EPS loss of $1.19. Eight firms follow Keryx and five rate KERX shares as a “Hold”, one rates it as a “Buy”, and two rate KERX shares as a “Strong Buy”. Their consensus price target is $7.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol KERX
Last Price a/o 2:33 PM EST  $                      5.39
Average Volume                1,580,000
Market Cap (mlns)  $                  506.49
Sales (mlns) $28.20
Shares Outstanding (mlns) 105.96
Share Float (mlns) 101.78
Shortable Yes
Optionable Yes
Inside Ownership 0.69%
Short Float 20.54%
Short Interest Ratio 13.21
Quarterly Return 5.99%
YTD Return -18.43%
Year Return 38.95%

Benitec Biopharma (Nasdaq: BNTC) Doubles!

Benitec Biopharma Limited – Nasdaq: BNTC

Shares of Benitec Bipharma are more than double yesterday’s closing price and surged to an inter-day high of $4.44 before settling down to $3.50 in mid-day trading. BNTC, traded on the Nasdaq, shares normally have an average daily volume of less than 200k, but today more than seven million shares have traded almost two hours before market close.

The Australian-based company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases. Benitec Biopharma is a biotechnology company developing a proprietary therapeutic technology platform that combines gene silencing and gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. Benitec Biopharma is using DNA-directed RNA interference, or ddRNAi, to develop a pipeline of product candidates for the treatment of several chronic and life-threatening human diseases, such as hepatitis B, age-related macular degeneration, or AMD and oculopharyngeal muscular dystrophy, or OPMD.

Benitec Biopharma has no reported sales. BNTC has no EPS. Only one firm rates BNTC shares it gives it a rating of “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol BNTC
Last Price a/o 1:28 PM EST  $                      3.45
Average Volume                    176,560
Market Cap (mlns)  $                  234.45
Sales (mlns) $7.19
Shares Outstanding (mlns) 146.53
Share Float (mlns) 5.49
Shortable Yes
Optionable No
Inside Ownership
Short Float 0.49%
Short Interest Ratio 0.15
Quarterly Return 7.53%
YTD Return 4.58%
Year Return -54.29%

BioDelivery Sciences Int’l (Nasdaq: BDSI) Gains on CEO Comments

BioDelivery Sciences International Inc. – Nasdaq: BDSI

Yesterday BioDelivery Sciences International President and CEO Mark Sirgo gave shareholders good news. Today shares (BDSI) are responding by gaining over 7% in early trading on the Nasdaq. Sirgo stated to a conference that he forecasts increasing profitability due to the reacquisition of licensing rights to Belbuca, a pain management drug. Sirgo stated “On Jan. 6, we inherited a product on very favorable financial terms that ended the year with a $30 million gross sales run rate”

BioDelivery Sciences International is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI utilizes proprietary BioErodible MucoAdhesive and other drug delivery technologies to develop and commercialize new applications of proven therapies aimed at addressing important unmet medical needs. BDSI’s marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.

BDSI has increased year-on-year sales for the past three years and in 2015 BDSI reported a figure of $48.2 million. EPS for BDSI also has been improving though still negative. In 2013 EPS for BDSI was a loss of $1.51 but improved to a smaller loss of $0.72 in 2015. Seven firms follow BioDelivery Sciences. Six rate BDSI shares as a “Strong Buy” and one rates the shares as a “Hold”. Their consensus price target for BDSI is $4.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol PLUG
Last Price a/o 8:43 AM EST  $                      2.05
Average Volume                    606,540
Market Cap (mlns)  $                  102.79
Sales (mlns) $43.80
Shares Outstanding (mlns) 54.1
Share Float (mlns) 51.34
Shortable Yes
Optionable Yes
Inside Ownership 1.10%
Short Float 8.65%
Short Interest Ratio 7.32
Quarterly Return -17.39%
YTD Return 8.57%
Year Return -52.14%

EnteroMedics (Nasdaq: ETRM) Continues Rise

EnteroMedics Inc. – Nasdaq: ETRM

EnteroMedics Inc. continues to post double-digit moves. Wednesday saw the price rise almost 40% to $8.70 and has touched as high as $9.90 in Thursday pre-market trading. In the first week of 2017, ETRM, traded on the Nasdaq, gained over 1,000%, then gave up much of its gains. EnteroMedics has developed and marketed a pacemaker-like device that addresses obesity, metabolic diseases, and other gastrointestinal disorders. The vBloc device is now available for implantation at thirteen healthcare facilities in the USA. Trade chat rooms are showing heavy activity on ETRM and volumes have been heavy.

vBloc Therapy works to control sensations of hunger using a pacemaker-like device that is implanted under the skin during a safe, minimally-invasive procedure that does not alter or remove any patient anatomy. Patients feel the sensation of fullness, empowering them to eat less, control their appetite, make healthier choices and lose weight without the major lifestyle implications of traditional weight loss surgeries.

vBloc Therapy is approved for use in helping with weight loss in people aged 18 years and older who are obese with a related health condition such as Type 2 diabetes, high blood pressure, high cholesterol levels or obstructive sleep apnea who have had a poor response to trying to lose weight under supervision in the last 5 years.

On January 23, EnteroMedics announced the closing of an underwritten public offering of units for gross proceeds of $19.0 million. A total of 751,412 shares of ETRM common stock, 12,531 shares of preferred stock convertible into 2,359,887 shares of common stock, and warrants to purchase 3,111,299 shares of ETRM common stock were issued in the offering.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol ETRM
Last Price a/o 7:22 AM EST  $                      8.90
Average Volume              12,490,000
Market Cap (mlns)  $                    29.41
Sales (mlns) $0.80
Shares Outstanding (mlns) 3.51
Share Float (mlns) 3.48
Shortable Yes
Optionable Yes
Inside Ownership 0.00%
Short Float 33.44%
Short Interest Ratio 0.09
Quarterly Return 9984.24%
YTD Return 319.00%
Year Return 874.42%

Infinity Pharmaceuticals (Nasdaq: INFI) Up 20%+ on Large Volumes

Infinity Pharmaceuticals Inc. – Nasdaq: INFI

Infinity Pharmaceuticals shares, traded on the Nasdaq under ticker INFI, were up over 20% in today’s trading. INFI ended Tuesday at $2.07 and rose to an inter-day high of $2.55 today before settling at $2.51 on heavy volumes.

Today’s price is the highest INFI shares have been since June, 2016 when disappointing news on one of its drug candidates led to a large price breakdown. Cambridge, MA-based Infinity Pharmaceuticals is a biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is, in conjunction with Bristol-Meyers (NYSE: BMY, developing IPI-549, an oral immuno-oncology development candidate. A Phase 1 study in patients with advanced solid tumors is ongoing.

Infinity Pharmaceuticals experienced negative sales growth in 2015 when it reported $109.1 million compared to $165 million in 2014. INFI shareholders have not experienced positive EPS in the past five years. In 2015 INFI posted an EPS loss of $2.62.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Alcobra Ltd. (Nasdaq: ADHD) Rebounds from Poor Clinical Trial Results and Accusations

Alcobra Ltd. – Nasdaq: ADHD

Shares of Israeli-based Alcobra Ltd. are up over 20% on heavy volume. ADHD, traded on the Nasdaq, ended Tuesday trading at $1.05 and has risen to $1.33 in today’s trading. Normal average daily trading volumeis less than 600k shares but today shares have traded over four million.

Alcobra is a pharmaceutical company focused on the development and commercialization of their proprietary drug, Metadoxine Extended Release (MDX), to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (FXS).

On January 17, 2017 Alcobra released disappointing results from their Phase 3 clinical study. From Alcobra’s press release “In this trial, MDX did not meet the primary endpoint of demonstrating a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners’ Adult ADHD Rating Scales (CAARS).” Also on Janbuary 17, 2017 it was also announced by several law firms that they were initiating an investigation of the company relating to possible violations of federal securities laws. Shares ended down more than 50% for the day.

Alcobra has never achieved any sales. EPS for ADHD shares has been negative for the past five years and in 2015 ADHD shareholders experienced an EPS loss of $0.90.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/1/2017
Ticker Symbol ADHD
Last Price a/o 3:51 PM EST  $                      1.28
Average Volume                    565,840
Market Cap (mlns)  $                    28.93
Sales (mlns)
Shares Outstanding (mlns) 27.55
Share Float (mlns) 23.56
Shortable Yes
Optionable Yes
Inside Ownership 30.00%
Short Float 5.96%
Short Interest Ratio 2.48
Quarterly Return -45.31%
YTD Return -50.00%
Year Return -79.92%

Galectin Therapeutics (Nasdaq: GALT) Announces New Financing and Clinical Milestones

Galectin Therapeutics Inc. – Nasdaq: GALT

Norcross, GA-based Galectin Therapeutics announced today that it has generated sufficient financing to cover currently planned expenditures through 2017 and it remains on track to present top line data from its NASH-CX Phase 2 clinical trial by early December 2017. Shares of Galectin Therapeutics are traded on the Nasdaq under ticker GALT.

Galectin Therapeutics is a biotechnology company that discovers and develops new therapies for fibrotic disease and cancer. Drug candidates based on their proprietary carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics persues therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease.

Galectin Therapeutics has reached clinical milestones in its NASH-CX trial, a double blind, placebo-controlled Phase 2b clinical trial. To date, 47 patients have completed all 52 weeks of infusions with the company’s lead compound, GR-MD-02, and 122 patients have completed 26 weeks of infusions. In the NASH-CX clinical trial, more than 3,000 infusions (or 75% of the maximum infusions in the trial) have been administered with no drug-related serious adverse reactions. Only 8 patients have discontinued participation in the clinical trial before their scheduled completion dates, and none of the discontinuations were due to drug-related serious adverse events. Currently, the approximate 5% dropout rate is significantly below the 25% included as part of the trial design. The top-line data readout of the NASH-CX trial remains on track for early December 2017.

GALT EPS has been negative for the past five years. In 2015 GALT’s EPS loss was $0.88. Three firms follow Galectin. Two rate GALT shares as a “Hold” and one rates the shares as a “Sell”. The consensus price target for GALT is $0.75.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.